YU62499A - Nova so - Google Patents
Nova soInfo
- Publication number
- YU62499A YU62499A YU62499A YU62499A YU62499A YU 62499 A YU62499 A YU 62499A YU 62499 A YU62499 A YU 62499A YU 62499 A YU62499 A YU 62499A YU 62499 A YU62499 A YU 62499A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- tartrate
- salt
- new salt
- dicyclobutylamino
- benzopyran
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Nova so (R)-3-N,N-diciklobutil-amino-8-fluor-3,4-dihidro-2H-1-benzopiran-5-karboksamid vodonik tartrat, naročito njen (2R,3R)-tartrat, a posebno monohidrat (R)-3-N,N-diciklobutil-amino-8-fluor-3,4-dihidro-2H-1-benzopiran-5-karboksamid vodonik (2R, 3R)-tartrat, postupak za proizvodnju ove soli tartrata, primena soli u medicini, primena soli tartrata u proizvodnji farmaceutskih formulacija, i postupak za lečenje oboljenja centralnog nervnog sistema davanjem soli tartrata domaćinu kome je potrebno takvo lečenje.[A new salt (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen tartrate, particularly the (2R, 3R)-tartrate thereof, most particularly the (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate, processes for the manufacture of said tartrate salt, the use of the salt in medicine, the use of the tartrate salt in the manufacture of pharmaceutical formulations, and a method for the treatment of CNS disorders by administration of the tartrate salt to a host in need of such treatment.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702066A SE510305C2 (sv) | 1997-05-30 | 1997-05-30 | Nytt salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU62499A true YU62499A (sh) | 2002-06-19 |
Family
ID=20407187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU62499A YU62499A (sh) | 1997-05-30 | 1998-05-15 | Nova so |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US6858645B2 (sh) |
| EP (1) | EP0984952B1 (sh) |
| JP (1) | JP3554338B2 (sh) |
| KR (1) | KR20010013127A (sh) |
| CN (1) | CN1198814C (sh) |
| AR (1) | AR012751A1 (sh) |
| AT (1) | ATE228121T1 (sh) |
| AU (1) | AU729301B2 (sh) |
| BG (1) | BG64051B1 (sh) |
| BR (1) | BR9809519A (sh) |
| CA (1) | CA2291732C (sh) |
| DE (1) | DE69809547T2 (sh) |
| DK (1) | DK0984952T3 (sh) |
| EE (1) | EE03874B1 (sh) |
| ES (1) | ES2187030T3 (sh) |
| HK (1) | HK1025575A1 (sh) |
| HU (1) | HUP0001878A3 (sh) |
| ID (1) | ID23794A (sh) |
| IL (1) | IL133234A (sh) |
| IS (1) | IS1943B (sh) |
| MY (1) | MY117960A (sh) |
| NO (1) | NO995853L (sh) |
| NZ (1) | NZ501075A (sh) |
| PL (1) | PL337181A1 (sh) |
| PT (1) | PT984952E (sh) |
| RU (1) | RU2193560C2 (sh) |
| SE (1) | SE510305C2 (sh) |
| SK (1) | SK282755B6 (sh) |
| TR (1) | TR199902926T2 (sh) |
| TW (1) | TW510899B (sh) |
| UA (1) | UA53720C2 (sh) |
| WO (1) | WO1998054166A1 (sh) |
| YU (1) | YU62499A (sh) |
| ZA (1) | ZA984486B (sh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102888D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| SE0102886D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| SE0301795D0 (sv) * | 2003-06-19 | 2003-06-19 | Astrazeneca Ab | New use I |
| SE0301796D0 (sv) * | 2003-06-19 | 2003-06-19 | Astrazeneca Ab | New use II |
| ATE528807T1 (de) * | 2006-05-11 | 2011-10-15 | Johnson Controls Saft Advanced Power Solutions Llc | Modulares batteriesystem |
| JP5163931B2 (ja) * | 2007-03-08 | 2013-03-13 | 株式会社リコー | 定着装置及び画像形成装置 |
| EP2065385A1 (en) * | 2007-11-28 | 2009-06-03 | Laboratorios SALVAT, S.A. | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
| CN103788043B (zh) * | 2008-11-28 | 2016-02-03 | 中国医学科学院药物研究所 | 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途 |
| CA2910085C (en) * | 2013-04-26 | 2021-05-25 | Sanofi | Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(s)-2-[methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propryl]amide |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616610A (en) | 1989-12-22 | 1997-04-01 | Astra Aktiebolag | (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans |
| US5420151A (en) | 1989-12-22 | 1995-05-30 | Aktiebolaget Astra | Chroman derivatives |
| IT1282705B1 (it) | 1996-02-28 | 1998-03-31 | Recordati Chem Pharm | Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria |
| US5990114A (en) | 1996-02-28 | 1999-11-23 | Recordati, S.A., Chemical And Pharmaceutical Company | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence |
-
1997
- 1997-05-30 SE SE9702066A patent/SE510305C2/sv not_active IP Right Cessation
-
1998
- 1998-05-13 TW TW087107397A patent/TW510899B/zh active
- 1998-05-15 NZ NZ501075A patent/NZ501075A/en unknown
- 1998-05-15 CA CA002291732A patent/CA2291732C/en not_active Expired - Fee Related
- 1998-05-15 EP EP98925993A patent/EP0984952B1/en not_active Expired - Lifetime
- 1998-05-15 US US09/077,718 patent/US6858645B2/en not_active Expired - Fee Related
- 1998-05-15 JP JP50056099A patent/JP3554338B2/ja not_active Expired - Fee Related
- 1998-05-15 IL IL13323498A patent/IL133234A/en not_active IP Right Cessation
- 1998-05-15 UA UA99127241A patent/UA53720C2/uk unknown
- 1998-05-15 YU YU62499A patent/YU62499A/sh unknown
- 1998-05-15 BR BR9809519-6A patent/BR9809519A/pt not_active IP Right Cessation
- 1998-05-15 ID IDW991407A patent/ID23794A/id unknown
- 1998-05-15 RU RU99128026/04A patent/RU2193560C2/ru not_active IP Right Cessation
- 1998-05-15 AU AU77923/98A patent/AU729301B2/en not_active Ceased
- 1998-05-15 AT AT98925993T patent/ATE228121T1/de not_active IP Right Cessation
- 1998-05-15 KR KR19997011107A patent/KR20010013127A/ko active IP Right Grant
- 1998-05-15 CN CNB988056631A patent/CN1198814C/zh not_active Expired - Fee Related
- 1998-05-15 PT PT98925993T patent/PT984952E/pt unknown
- 1998-05-15 HU HU0001878A patent/HUP0001878A3/hu unknown
- 1998-05-15 DK DK98925993T patent/DK0984952T3/da active
- 1998-05-15 DE DE69809547T patent/DE69809547T2/de not_active Expired - Fee Related
- 1998-05-15 SK SK1594-99A patent/SK282755B6/sk unknown
- 1998-05-15 TR TR1999/02926T patent/TR199902926T2/xx unknown
- 1998-05-15 EE EEP199900549A patent/EE03874B1/xx not_active IP Right Cessation
- 1998-05-15 PL PL98337181A patent/PL337181A1/xx unknown
- 1998-05-15 ES ES98925993T patent/ES2187030T3/es not_active Expired - Lifetime
- 1998-05-15 WO PCT/SE1998/000907 patent/WO1998054166A1/en not_active Application Discontinuation
- 1998-05-26 ZA ZA984486A patent/ZA984486B/xx unknown
- 1998-05-26 AR ARP980102434A patent/AR012751A1/es unknown
- 1998-05-29 MY MYPI98002400A patent/MY117960A/en unknown
-
1999
- 1999-11-24 IS IS5270A patent/IS1943B/is unknown
- 1999-11-29 NO NO995853A patent/NO995853L/no not_active Application Discontinuation
- 1999-12-03 BG BG103949A patent/BG64051B1/bg unknown
-
2000
- 2000-08-08 HK HK00104934A patent/HK1025575A1/xx not_active IP Right Cessation
-
2004
- 2004-10-12 US US10/964,388 patent/US20050085532A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| TW200510375A (en) | New compounds | |
| EP1933833B8 (en) | Therapy for the treatment of overactive bladder | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| IN2015DN01132A (sh) | ||
| MXPA02005536A (es) | Acidos aminopropilfosfinicos novedosos. | |
| IS1904B (is) | Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum | |
| YU62499A (sh) | Nova so | |
| PL370529A1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | |
| SE0102440D0 (sv) | New compound | |
| WO2004105690A3 (en) | Treatment of chronic pain associated with drug or radiation therapy | |
| DK1091733T3 (da) | (-)-Pseudoephedrin som et sympatomimetisk lægemiddel | |
| HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
| HUP0300863A2 (hu) | N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény | |
| EP0657167A3 (fr) | Application de l'oenothéine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, les compositions pharmaceutiques le contenant et un procédé de préparation à partir d'Epilobium Parviflorum. | |
| BG108452A (en) | Tablet comprising cetirizine and pseudoephedrine | |
| MY133438A (en) | Morpholinobenzamide salts | |
| HUP0103544A2 (hu) | (R)-3-(N,N-diciklobutil amino)-8-fluor-3,4dihidro-2H-1-benzopirán-5karboxamid-hidrogén-(2R,3R)tartarát monohidrátot és paroxelint tartalmazó gyógyszerkészítmény és eljárás az előállítására | |
| AU6470400A (en) | Nitroxy derivatives of (r) and (s)-carnitine | |
| EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders | |
| UA88284C2 (ru) | Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения | |
| SE0102888D0 (sv) | New formulation | |
| PL367628A1 (en) | Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia | |
| HUP0103992A2 (hu) | Pregnán-glükuronidok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| CA2532330A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same |